[Question] does the glucagon arm explain the heart rate signal
Trying to get a straight answer on this: does the glucagon arm explain the heart rate signal.
The escalation schedules in the published protocols are slow and deliberate, and the tolerability tables show why. That is a description of the trials rather than a suggestion for anybody.
Phase 2 in a biopsy-confirmed population is a demanding design: recruitment is slow, the population is specific, and the results do not generalise to people who have not been characterised that way.
Imaging-derived liver fat fraction is a surrogate. It correlates with histology imperfectly, and a trial reporting one is not reporting the other.
If somebody has the same thing measured a different way, post it next to mine and we will see whether they agree.
best — the order this archive was captured in
It is a dual agonist at the GLP-1 and glucagon receptors. The glucagon arm is associated with increased energy expenditure and with effects on hepatic fat, which is why the development programme is oriented towards liver disease.
Histological endpoints in this field are scored on biopsy: resolution of steatohepatitis without worsening of fibrosis, or improvement in fibrosis without worsening of steatohepatitis. Both are harder to achieve and to interpret than an imaging surrogate.
Which endpoint — histological response, fibrosis improvement, or fat fraction?
Which endpoint — histological response, fibrosis improvement, or fat fraction?
This is the framing the board needs. It is a hepatic programme first.
Histological endpoints in this field are scored on biopsy: resolution of steatohepatitis without worsening of fibrosis, or improvement in fibrosis wit
Disagreeing with this bit: that number comes from a different programme with a different population.
research material is not approved for human use, which is why the clinical record here is thin
Biopsy-confirmed population or imaging-selected?
the weight numbers are secondary to what this is being developed for
Independent purity results for this compound are very sparse across the whole site, which means any impression about consistency is built on almost nothing.
MASH endpoints are histological, which is a much harder bar
Nothing containing this compound is approved anywhere. Research-use-only material is not approved for human use.
Nothing containing this compound is approved anywhere.
Adding the standing caveat — unapproved compound, research material is not for human use.
Correction: that is the imaging endpoint, not the histological one. The paper reports both and they differ substantially.
- 1It is a dual agonist at the GLP-1 and glucagon receptors. The glucagon arm…11 comments in this branch · started by u/kaia_cabrera